How much does a box of Ribociclib cost?

Ribociclib (Ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinases 4 and 6 (CDK4/6). When these proteins Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably when they are overactivated. Ribocil was approved by the US Food and Drug Administration (FDA) as Kisqali in March 2017.

Riboxiclib may be used to treat hormone receptor-positive breast cancer in women if the cancer has spread to other parts of the body or is locally advanced. As part of hormone therapy, in combination with an aromatase inhibitor or the anti-estrogen drug fulvestrant. Riboxiclib can be used both as first-line hormonal therapy and as follow-up treatment if previous hormonal therapy has been unsuccessful. In premenopausal and perimenopausal women, rebociclib is used in combination with GnRH analogues. If possible, patients may undergo surgery to remove breast tumors. But sometimes the tumor becomes too large or the cancer has spread to other parts of the body through the blood or lymphatic system (metastasis).

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.